Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Sponsor

NKGen Biotech, Inc. (Industry)

Overall Status

Active, not recruiting

CT.gov ID

NCT03941262

Collaborator

(none)

Enrollment

Location

Arms

40.6

Anticipated Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate the safety and preliminary efficacy of SNK01 (autologous natural killer cell), as a single agent and in combination with avelumab or pembrolizumab, for the treatment of subjects with advanced and/or metastatic refractory cancer that has failed three or more prior lines of conventional standard of care therapy.

Condition or Disease	Intervention/Treatment	Phase
Refractory Cancer Metastatic Cancer Recurrent Cancer Unresectable Carcinoma Solid Tumor, Adult Advanced Cancer Advanced Solid Tumor	Biological: SNK01 Drug: Avelumab Drug: Pembrolizumab	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

27 participants

Allocation:

Non-Randomized

Intervention Model:

Sequential Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase 1, Open-Label, Safety Study of Escalating Doses of Ex Vivo Expanded, Autologous Natural Killer Cells in Patients With Pathologically Confirmed Cancer Refractory to Conventional Therapy

Actual Study Start Date :

Jul 15, 2019

Anticipated Primary Completion Date :

Aug 1, 2022

Anticipated Study Completion Date :

Dec 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Cohort 1 - Low dose SNK01 SNK01 (low dose) administered once a week for five weeks.	Biological: SNK01 Patient-specific ex vivo expanded autologous natural killer cells
Experimental: Cohort 2 - Medium dose SNK01 SNK01 (medium dose) administered once a week for five weeks.	Biological: SNK01 Patient-specific ex vivo expanded autologous natural killer cells
Experimental: Cohort 3 - High dose SNK01 SNK01 (high dose) administered once a week for five weeks.	Biological: SNK01 Patient-specific ex vivo expanded autologous natural killer cells
Experimental: Cohort 4 - SNK01 with avelumab SNK01 (high dose) administered in combination with avelumab once every two weeks (14-day cycle) for five cycles.	Biological: SNK01 Patient-specific ex vivo expanded autologous natural killer cells Drug: Avelumab Avelumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death-ligand 1 (PD-L1). Other Names: Bavencio
Experimental: Cohort 4 - SNK01 with pembrolizumab SNK01 (high dose) administered in combination with pembrolizumab once every three weeks (21-day cycle) for five cycles.	Biological: SNK01 Patient-specific ex vivo expanded autologous natural killer cells Drug: Pembrolizumab Pembrolizumab is a humanized monoclonal antibody immune checkpoint blockade immunotherapy that targets the programmed cell death receptor-1 (PD-1). Other Names: Keytruda

Outcome Measures

Primary Outcome Measures

To assess the safety profile [Up to 6 months]
Assessed by the incidence and severity of dose limiting toxicity (DLT) and other adverse events graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 5.0, or the cytokine release syndrome revised grading system.

Secondary Outcome Measures

To assess clinical objective response rate (ORR) of SNK01 in patients with refractory cancer [Up to 12 months]
Objective response rate (ORR) is defined by the percentage of subjects who achieve a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.
To assess clinical objective response rate (ORR) of SNK01 in combination with avelumab in patients with refractory cancer [Up to 12 months]
Objective response rate (ORR) is defined by the percentage of subjects who achieve a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.
To assess clinical objective response rate (ORR) of SNK01 in combination with pembrolizumab in patients with refractory cancer [Up to 12 months]
Objective response rate (ORR) is defined by the percentage of subjects who achieve a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Voluntary written informed consent signed by patient, obtained prior to study enrollment.
Males and females ages 18 to 75 years, inclusive.
Pathologically confirmed diagnosis of refractory cancer that has failed three or more prior lines of conventional standard of care therapy.
Diagnosed with any histologically confirmed malignancy whose disease is confirmed to be metastatic and/or unresectable for which standard curative or beneficial treatments are no longer effective.
Eastern Cooperative Oncology Group (ECOG) performance status <2.
At least 4 weeks since any prior systemic therapy (excluding corticosteroid therapy) to treat the underlying malignancy (standard or investigational).
At least 2 weeks since prior palliative radiotherapy.
Adequate bone marrow function:
Neutrophils: 2.0-8.0 K/uL
Platelet Count: 140-440 K/uL
Hemoglobin: 10.0-18.0 g/dL
No ongoing transfusion requirements
Adequate hepatic function:
Serum total bilirubin < 1.5 x upper limit of normal (ULN)
Serum albumin ≥ 3.0 g/dL
Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 x ULN
International normalized ratio (INR) ≤ 1.5 x ULN
Adequate renal function with creatinine ≤ 2.0 mg/dL.
Negative pregnancy test for women of childbearing potential and use of effective contraception (hormonal or barrier method of birth control) during study.

Exclusion Criteria:

Pregnant and/or lactating females.
Life expectancy of less than three months.
Currently being treated by "biological therapy" as defined by the National Cancer Institute (example: checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies, treatment vaccines, cytokines, Bacillus Calmette-Guerin (BCG), chimeric antigen receptor T cell therapy (CAR-T), and natural killer cell therapy).
Patients tested positive for hepatitis B and/or C surface antigen.
High fever or any active or unresolved infection, including human immunodeficiency virus (HIV) positive.
Autoimmune disease requiring therapy; immunodeficiency, or any disease process requiring immunosuppressive therapy.
Prior clinical trial requiring patient to receive an investigational drug within two weeks of enrollment.
Congestive heart failure, unstable angina or other underlying cardiac disease; history of thrombosis currently requiring anticoagulation.
Mental or psychological illness preventing cooperation with treatment, efficacy evaluations, or unable to understand the informed consent process.
Subjects who have undergone prior organ transplantation, including allogeneic stem-cell transplantation.
Adult subjects who lack capacity to consent for themselves and for whom consent must be provided by a legally authorized representative.
For SNK01+avelumab arm only: Subjects with prior hypersensitivity to avelumab or its excipients, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
For SNK01+avelumab arm only: Subjects with a significant immune-mediated adverse event due to a prior checkpoint inhibitor immunotherapy that led to permanent discontinuation of the therapy.